AlphAIAlphAI — Financial news for AI agents
uk.investing.comSEP 82 min read$SRPT

Mizuho reiterates Sarepta stock rating after Novartis trial miss

Mizuho reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (SRPT), stating the sell-off after Novartis' failed trial is excessive. The firm noted that Novartis' del-desiran showed clinical activity in secondary endpoints, which may aid Sarepta's SRP-1003 development. SRPT stock fell 10% following the news but remains up 35% over six months. The company recently reported Q2 2026 earnings of $0.64 per share, exceeding estimates, with revenue at $401.3 million.

Original reporting
uk.investing.com
Published Sep 8, 2026, 3:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SRPT
Bullish
high confidence
Mentioned
$SRPT
Relevance
8/10
AlphAI data visualization · based on uk.investing.com
Decision brief

The 30-second read

$SRPTBullishMed
01

Why it matters

Earnings beat and upgraded rating provide a fresh catalyst for price appreciation, though trial miss risk remains.

02

Market read

The news offers a short‑term trading opportunity on SRPT with upside potential, while highlighting sector‑wide biotech sentiment.

03

What to watch

Potential regulatory delays for SRP-1003 and reliance on secondary endpoints.

Relevance 8/10Novelty 8/10Timing: post-market

Background

Sarepta Therapeutics (SRPT) faced a sell‑off after Novartis' failed DM1 trial, but Mizuho now sees the dip as overdone and the company posted a strong Q2 earnings beat.

Company-level read

Ticker impact

$SRPTBullishHigh confidence
Context

Mizuho reiterates Outperform rating and $31 price target for Sarepta Therapeutics after its Q2 earnings beat expectations and after the Novartis trial miss.

Expected impact

Potential short-term rally toward $31 target.

Evidence & confidence

Beat on EPS ($0.64 vs $0.22) and revenue beat, combined with fresh analyst rating, provide a clear catalyst.

Market effects

Sector

Positive earnings may lift broader biotech sector sentiment.

Regional

U.S. biotech stocks could see modest gains.

Global

Limited to biotech investors; no broad macro effect.

Counterpoint

What could challenge this read

The Novartis trial miss could still weigh on SRPT if downstream data disappoints.

Key entities

  • company
    Sarepta Therapeutics

    Biotech firm developing SRP-1003 for Duchenne muscular dystrophy.

  • analyst
    Mizuho

    Equity research firm reiterating Outperform rating.

Read at source← All news

Related articles

SEP 8
$SRPTMed

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook

Jefferies reiterated a Buy rating and $30.00 price target for Sarepta Therapeutics (SRPT), citing potential 40% upside. The firm expects Phase I/II trial data in 2H 2026, with competitive results potentially driving significant stock movement. SRPT reported Q2 2026 earnings beating estimates, with EPS of $0.64 vs. $0.22 forecasted and revenue of $401.3M vs. $383M expected. Mizuho also reiterated an Outperform rating with a $31.00 target.

investing.com2 min
SEP 8
$SRPTHighAI 8/10

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (SRPT) stock fell 8.09% after Novartis (NVS) reported Phase 3 trial results for del-desiran in myotonic dystrophy type 1 (DM1) that did not meet primary endpoints. Sarepta is developing SRP-1003 for DM1, with Phase 1/2 data expected in late 2026. The company noted positive early data and potential for optimized dosing. SRPT is above short-term moving averages but below the 200-day SMA, indicating mixed signals.

benzinga.com2 min
SEP 8
$SRPTHighAI 8/10

Why is Sarepta Therapeutics stock sliding today?

Sarepta Therapeutics (SRPT) stock fell 7.6% in pre-market trading after Novartis' (NVS) Phase III trial failure for a neuromuscular disease treatment, impacting investor confidence in the therapeutic class. Several other pharmaceutical stocks, including AMGN, LLY, IONS, and DYN, also declined. Sarepta faces additional challenges with tightened 2026 revenue guidance and regulatory uncertainty. The broader market's risk-off tone amplified the sell-off, with SRPT trading at $20.80, below its 52-wee

investing.com2 min
AUG 19
$SRPTMedAI 8/10

Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline

Sarepta Therapeutics reported Q2 2026 net product revenue of $328.7M, with GAAP operating income of $13.3M and non-GAAP operating income of $86.5M. The company appointed Michael Severino as CEO and narrowed its 2026 revenue guidance to $1.2B-$1.3B. Sarepta's pipeline includes treatments for Duchenne muscular dystrophy (DMD) and other rare diseases, with key data readouts expected in the second half of 2026. Analysts have mixed ratings and price targets for the company.

streetwisereports.com2 min
AUG 13
$SRPTMedAI 8/10

Sarepta (SRPT) Q2 2026 Earnings Call Transcript

Sarepta Therapeutics (SRPT) reported Q2 2026 results on an earnings call. Total revenue was $401.3M, down 34% YoY, with net product revenue $328.7M. Non-GAAP diluted EPS was $0.64. Cash and investments rose to $945.0M. 2026 product revenue guidance was narrowed to $1.2B-$1.3B, and Roche milestone and collaboration revenue were discussed.

fool.com7 min